Mastodawn

Healthcare worker infections highlight risks to frontline staff and the urgent need for better surveillance, testing, PPE, and infection control. International health organizations are enhancing response as authorities stress early detection and contact tracing to contain transmission and strengthen global public health preparedness.

Read Full- https://economicsperspective.com/worldnews/ebola-bundibugyo-virus-WHO/

#worldhealthorganization #publichealth #viruses #worldnews #BreakingNews #globalnews #healtheconomics

MedBridgeNZ May 9

Imagine looking at two totally different medical bills for the exact same complex spinal fusion surgery. One is from an American hospital for a staggering $262,000 , and the other is from a hospital in China for just $14,000. The $14k procedure wasn't performed in a back-alley clinic; it was executed using a cutting-edge surgical robot with zero wait time. The narrative of global healthcare is completely flipping.

#MedicalTourism #HealthcareCrisis #SpineSurgery #HealthEconomics

WiSoFakultät_UniKöln May 5

🎓 Two degrees, one healthcare impact

🌍 Double Master’s in Health Economics & Management

✨ 2 M.Sc. in 4 semesters
✨ Study in Cologne & Maastricht
✨ Focus on policy, systems & innovation

🌐 For future healthcare changemakers

🔗https://uni.koeln/ZC24E

#DoubleDegree #HealthEconomics #UniCologne #Healthcare

Show thread

Lee Crowther May 1

I learned about #MasarykUniversity beginning an interdisciplinary master's in applied #HealthEconomics. I liked that the program brought in experts from #Economics, #Medicine, #Science, #Pharmacy, #Law, and #SocialStudies, and that the subject matter incorporated insights from multiple countries' health systems. Last fall, I moved to the #CzechRepublic to join the inaugural cohort. 2/6

Milano University Press Apr 28

🔬 The latest issue of #EBPH, the official journal of the Italian Society of Medical Statistics and Clinical Epidemiology #SISMEC, is now fully online

A multidisciplinary journal that places key #PublicHealth challenges at its core, featuring original studies, systematic reviews, meta-analyses, and research protocols on #HealthPolicies, #HealthcareManagement, and #healtheconomics

⬇️ In #openaccess here:
https://riviste.unimi.it/index.php/ebph/issue/view/2720?mtm_campaign=mastodon

#newissue #healthcare #academia

Vol. 21 No. 1 (2026) | Epidemiology, Biostatistics, and Public Health

AbangeLabs Apr 3

Target trial emulation is getting harder to ignore in HTA: registry-based RWD shifted the ICER for post-first-line RA biologics from ~£34.7k to ~£46.8k/QALY. https://www.mattheneus.com/editorial/target-trial-emulation-rwd-cost-effectiveness-hta-playbook-2026-04-03 #HTA #RWE #HealthEconomics

Target Trial Emulation May Be the Missing Bridge Between Real-World Data and Cost-Effectiveness in Health Technology Assessment

On 3 April 2026, Singh and colleagues published a Med Decision Making study showing that target trial emulation using registry-based real-world data changed the estimated cost effectiveness of biologic treatment after first-line failure in rheumatoid arthritis, lifting the incremental cost-effectiveness ratio from about £34,700 per quality-adjusted life-year in the randomized-trial-only analysis to about £46,800 when real-world evidence informed the estimate.

AbangeLabs Editorial

AbangeLabs Apr 2

CAR-T access is no longer just a clinical story; HTA timing and cost-effectiveness design now shape who gets to market and when.

https://www.mattheneus.com/editorial/car-t-global-hta-access-lag-cost-effectiveness-playbook-2026-04-02

#HTA #HealthEconomics #Pharma

Commercial chimeric antigen receptor (CAR) T-cell access now depends on earlier health technology assessment (HTA) and cost-effectiveness design

A new 2 April 2026 Blood analysis shows that commercial chimeric antigen receptor (CAR) T-cell access is being constrained as much by health technology assessment (HTA) timing and cost-effectiveness uncertainty as by manufacturing, forcing evidence teams to pre-build comparative and economic strategy before approval.

AbangeLabs Editorial

AbangeLabs Apr 2

HTA evidence teams are hitting a fragmentation wall: ITC, MAIC, NMA, RWE, modelling, and reporting now need one traceable workflow, not stitched-together handoffs. https://www.mattheneus.com/editorial/abangelabs-hta-studio-itc-foundation-end-to-end-hta-evidence-platform-2026-04-02 #HTA #NMA #MAIC #EvidenceSynthesis #HealthEconomics

AbangeLabs HTA Studio: From ITC Foundation to End-to-End HTA Evidence Platform

Health technology assessment (HTA) evidence teams are increasingly asked to deliver multi-method evidence packages spanning indirect treatment comparison (ITC), matching-adjusted indirect comparison (MAIC), network meta-analysis (NMA), economic modelling, and reporting. This article examines why fragmented execution is becoming a methodological governance risk and how AbangeLabs HTA Studio addresses that problem through documented current capabilities.

AbangeLabs Editorial

AbangeLabs Apr 2

HTA submissions keep breaking where comparative evidence meets the economic model. If the lineage is not traceable, cost-effectiveness and budget-impact claims turn fragile fast. https://www.mattheneus.com/editorial/hta-submissions-comparative-evidence-economic-model-lineage-problem-2026-04-02 #HTA #HealthEconomics #RegulatoryAffairs

Health technology assessment submissions now face a comparative-evidence to economic-model lineage problem

Health technology assessment (HTA) teams increasingly need cost-effectiveness and budget-impact outputs that remain directly traceable to the comparative evidence behind them. This article examines why broken lineage between analysis and modelling has become a submission risk and how AbangeLabs HTA Studio addresses that integration problem through verified current capabilities.

AbangeLabs Editorial

AbangeLabs Apr 2

HTA capacity doesn't scale through one-off pilots—it compounds through repeatable evidence, methods, and governance across countries. https://www.mattheneus.com/editorial/eastern-europe-central-asia-hta-capacity-building-governance-playbook-2026-04-02 #HTA #HealthEconomics #RegulatoryAffairs

Eastern Europe and Central Asia need a health technology assessment (HTA) capacity-building playbook, not one-off pilots

A 30 March 2026 International Journal of Technology Assessment in Health Care review shows that Eastern Europe and Central Asia are moving toward broader health technology assessment (HTA) use, but uneven staffing, training, and governance mean evidence teams need reusable cross-market comparative and economic packages rather than one-off country submissions.

AbangeLabs Editorial